| Dr Tim Gollan, MD, PHD | |
|
1236 Huffman Mill Rd Ste 130, Burlington, NC 27215-8700 | |
| (336) 438-1060 | |
| Not Available |
| Full Name | Dr Tim Gollan |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 22 Years |
| Location | 1236 Huffman Mill Rd Ste 130, Burlington, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891839262 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 2008-00538 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Moses H. Cone Memorial Hospital, The | Greensboro, NC | Hospital |
| Alamance Regional Medical Center | Burlington, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Moses H Cone Memorial Hospital Operating Corporation | 6204744600 | 496 |
News Archive
FEI is pleased to announce that researchers at the NIH-FEI Living Lab for Structural Biology have achieved breakthrough biological results, using FEI's Titan Krios™ transmission electron microscope (TEM), to elucidate the structural mechanism by which glutamate receptors participate in the transmission of signals between neurons in the brain. Their work is described in Nature, "Structural Mechanism of Glutamate Receptor Activation and Desensitization," by Meyerson, et al., (DOI: 10.1038/nature13603), http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13603.html .
Rigel Pharmaceuticals, Inc. today announced that it has received a milestone payment from Daiichi Sankyo Co., Ltd. as part of their collaboration to research and develop cancer treatments aimed at selectively inhibiting ligases, which are intrinsic to cancer cell growth and proliferation. The compound, as yet unnamed, targets cell division.
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center.
The American Gastroenterological Association (AGA) has announced the third class of its Future Leaders Program, which was created in 2015 to provide a pathway for leadership development within AGA for early career physicians and scientists who have the potential to make a significant impact on the specialty.
› Verified 4 days ago
| Entity Name | The Moses H Cone Memorial Hospital Operating Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356372064 PECOS PAC ID: 6204744600 Enrollment ID: O20031124000541 |
News Archive
FEI is pleased to announce that researchers at the NIH-FEI Living Lab for Structural Biology have achieved breakthrough biological results, using FEI's Titan Krios™ transmission electron microscope (TEM), to elucidate the structural mechanism by which glutamate receptors participate in the transmission of signals between neurons in the brain. Their work is described in Nature, "Structural Mechanism of Glutamate Receptor Activation and Desensitization," by Meyerson, et al., (DOI: 10.1038/nature13603), http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13603.html .
Rigel Pharmaceuticals, Inc. today announced that it has received a milestone payment from Daiichi Sankyo Co., Ltd. as part of their collaboration to research and develop cancer treatments aimed at selectively inhibiting ligases, which are intrinsic to cancer cell growth and proliferation. The compound, as yet unnamed, targets cell division.
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center.
The American Gastroenterological Association (AGA) has announced the third class of its Future Leaders Program, which was created in 2015 to provide a pathway for leadership development within AGA for early career physicians and scientists who have the potential to make a significant impact on the specialty.
› Verified 4 days ago
| Entity Name | Moses Cone Medical Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427095249 PECOS PAC ID: 2769395458 Enrollment ID: O20040128000519 |
News Archive
FEI is pleased to announce that researchers at the NIH-FEI Living Lab for Structural Biology have achieved breakthrough biological results, using FEI's Titan Krios™ transmission electron microscope (TEM), to elucidate the structural mechanism by which glutamate receptors participate in the transmission of signals between neurons in the brain. Their work is described in Nature, "Structural Mechanism of Glutamate Receptor Activation and Desensitization," by Meyerson, et al., (DOI: 10.1038/nature13603), http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13603.html .
Rigel Pharmaceuticals, Inc. today announced that it has received a milestone payment from Daiichi Sankyo Co., Ltd. as part of their collaboration to research and develop cancer treatments aimed at selectively inhibiting ligases, which are intrinsic to cancer cell growth and proliferation. The compound, as yet unnamed, targets cell division.
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center.
The American Gastroenterological Association (AGA) has announced the third class of its Future Leaders Program, which was created in 2015 to provide a pathway for leadership development within AGA for early career physicians and scientists who have the potential to make a significant impact on the specialty.
› Verified 4 days ago
| Entity Name | Moses Cone Affiliated Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346474103 PECOS PAC ID: 3779635396 Enrollment ID: O20090713000512 |
News Archive
FEI is pleased to announce that researchers at the NIH-FEI Living Lab for Structural Biology have achieved breakthrough biological results, using FEI's Titan Krios™ transmission electron microscope (TEM), to elucidate the structural mechanism by which glutamate receptors participate in the transmission of signals between neurons in the brain. Their work is described in Nature, "Structural Mechanism of Glutamate Receptor Activation and Desensitization," by Meyerson, et al., (DOI: 10.1038/nature13603), http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13603.html .
Rigel Pharmaceuticals, Inc. today announced that it has received a milestone payment from Daiichi Sankyo Co., Ltd. as part of their collaboration to research and develop cancer treatments aimed at selectively inhibiting ligases, which are intrinsic to cancer cell growth and proliferation. The compound, as yet unnamed, targets cell division.
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center.
The American Gastroenterological Association (AGA) has announced the third class of its Future Leaders Program, which was created in 2015 to provide a pathway for leadership development within AGA for early career physicians and scientists who have the potential to make a significant impact on the specialty.
› Verified 4 days ago
| Entity Name | The Moses H Cone Memorial Hospital Operating Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013265909 PECOS PAC ID: 6204744600 Enrollment ID: O20121003000518 |
News Archive
FEI is pleased to announce that researchers at the NIH-FEI Living Lab for Structural Biology have achieved breakthrough biological results, using FEI's Titan Krios™ transmission electron microscope (TEM), to elucidate the structural mechanism by which glutamate receptors participate in the transmission of signals between neurons in the brain. Their work is described in Nature, "Structural Mechanism of Glutamate Receptor Activation and Desensitization," by Meyerson, et al., (DOI: 10.1038/nature13603), http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13603.html .
Rigel Pharmaceuticals, Inc. today announced that it has received a milestone payment from Daiichi Sankyo Co., Ltd. as part of their collaboration to research and develop cancer treatments aimed at selectively inhibiting ligases, which are intrinsic to cancer cell growth and proliferation. The compound, as yet unnamed, targets cell division.
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center.
The American Gastroenterological Association (AGA) has announced the third class of its Future Leaders Program, which was created in 2015 to provide a pathway for leadership development within AGA for early career physicians and scientists who have the potential to make a significant impact on the specialty.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tim Gollan, MD, PHD 1200 N Elm St, Greensboro, NC 27401-1004 Ph: (336) 832-7000 | Dr Tim Gollan, MD, PHD 1236 Huffman Mill Rd Ste 130, Burlington, NC 27215-8700 Ph: (336) 438-1060 |
News Archive
FEI is pleased to announce that researchers at the NIH-FEI Living Lab for Structural Biology have achieved breakthrough biological results, using FEI's Titan Krios™ transmission electron microscope (TEM), to elucidate the structural mechanism by which glutamate receptors participate in the transmission of signals between neurons in the brain. Their work is described in Nature, "Structural Mechanism of Glutamate Receptor Activation and Desensitization," by Meyerson, et al., (DOI: 10.1038/nature13603), http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13603.html .
Rigel Pharmaceuticals, Inc. today announced that it has received a milestone payment from Daiichi Sankyo Co., Ltd. as part of their collaboration to research and develop cancer treatments aimed at selectively inhibiting ligases, which are intrinsic to cancer cell growth and proliferation. The compound, as yet unnamed, targets cell division.
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center.
The American Gastroenterological Association (AGA) has announced the third class of its Future Leaders Program, which was created in 2015 to provide a pathway for leadership development within AGA for early career physicians and scientists who have the potential to make a significant impact on the specialty.
› Verified 4 days ago
Dr. Ayesha Ali, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 729 Meadowood Dr, Burlington, NC 27215 Phone: 347-606-0485 | |
Mr. Dwayne Dennis Callwood, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1234 Huffman Mill Road, Burlington, NC 27215 Phone: 336-538-2374 Fax: 336-584-6811 | |
Dr. Fozia Muhstaqe Khan, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2991 Crouse Ln, Burlington, NC 27215 Phone: 336-586-0994 Fax: 336-586-9363 | |
Dr. Muhammad Arida, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1236 Huffman Mill Rd Ste 130, Burlington, NC 27215 Phone: 336-438-1060 | |
Janak Kantilal Choksi, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1236 Huffman Mill Rd, Suite #120, Burlington, NC 27215 Phone: 336-538-7725 Fax: 336-538-7785 | |
Dr. Anna Melissa Solum, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1234 Huffman Mill Rd, Burlington, NC 27215 Phone: 336-538-1234 Fax: 336-538-2390 | |
Dr. Munsoor Lateef, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2903 Professional Park Dr, Suite D, Burlington, NC 27215 Phone: 336-584-4913 Fax: 336-584-4914 |